Jenburkt Pharmaceuticals Limited (BOM:524731)

Market Cap	4.04B -12.8%
Revenue (ttm)	1.69B +9.1%
Net Income	328.30M +1.2%
EPS	74.39 +1.2%
Shares Out	4.41M
PE Ratio	12.31
Forward PE	n/a
Dividend	20.70 (2.26%)
Ex-Dividend Date	Aug 28, 2026

Volume	243
Open	942.00
Previous Close	916.00
Day's Range	916.05 - 952.45
52-Week Range	880.10 - 1,321.00
Beta	0.39
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 3, 2026

About Jenburkt Pharmaceuticals

Jenburkt Pharmaceuticals Limited manufactures and markets pharmaceutical formulations in India and internationally. The company offers therapeutic solutions, such as analgesic and antipyretics, anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants and antacids, aphrodisiac, atopic dermatitis, consumer division, cough and cold, muscle relaxants, neuropathic pain, nutraceuticals, and pain management. It offers its products under the Allerzine, CartiSafe Forte, Crisbo, Eberjen, ECOPROT, Frendacid...

• Industry: Pharmaceutical Preparations
• Founded: 1985
• Employees: 801
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524731

Financial Performance

In fiscal year 2026, Jenburkt Pharmaceuticals's revenue was 1.69 billion, an increase of 11.24% compared to the previous year's 1.52 billion. Earnings were 347.36 million, an increase of 8.34%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 17, 2026

Data Sources Report a data error